An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Stevanato Group (NYSE: STVN) announced participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, presenting virtually on March 22, 2022 at 9:00 a.m. EDT. A live audio webcast will be accessible on their website, with a replay available for 90 days post-event. The press release includes forward-looking statements regarding the company’s business strategies and recognizes the uncertainty in predicting future events. Founded in 1949, Stevanato Group specializes in drug containment and delivery solutions for the pharmaceutical and biotechnology sectors.
Positive
None.
Negative
None.
PIOMBINO DESE, Italy--(BUSINESS WIRE)--
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Management will present virtually at 9:00 a.m. EDT on Tuesday, March 22, 2022.
A live audio webcast will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section of the website. A replay will be available for approximately 90 days after the event.
Forward-Looking Statements
This press release may contain certain forward-looking statements which include, or may include, words such as “will”, "believe", "future", "expect", "foreseeable", "expected", "to be", "estimated", "assumes", "would provide", and other similar expressions (or their negative). Forward-looking statements contained in this press release include, but are not limited to, statements about our participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.
The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at their dates. Stevanato Group undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible to predict all of these factors. Further, Stevanato Group cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision.
About Stevanato Group Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.
When will Stevanato Group participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum?
Stevanato Group will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 22, 2022, at 9:00 a.m. EDT.
Where can I watch the webcast of Stevanato Group's presentation?
The live audio webcast of Stevanato Group's presentation can be viewed on their website under the 'Investors' section.
How long will the replay of Stevanato Group's presentation be available?
The replay of Stevanato Group's presentation will be available for approximately 90 days after the event.
What is the focus of Stevanato Group's business?
Stevanato Group focuses on drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries.
What does the press release say about forward-looking statements?
The press release includes forward-looking statements regarding Stevanato Group's business strategies and acknowledges the uncertainties in predicting future events.
